Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials

Table 3

Follow-up of patients with locally advanced rectal cancer receiving capecitabine/irinotecan +/− cetuximab based chemoradiotherapy as preoperative treatment ().

	Capecitabine/irinotecan	Capecitabine/irinotecan + cetuximab
Alive	23	36
Dead	14	13
Follow-up (months); median (range)	105.5 (1.3–133.7)	71.9 (7–103.3)